Table 7 Effects of nicotinamide riboside alone and nicotinamide riboside + resveratrol on exploratory muscle biopsy outcomes in people with peripheral artery disease
From: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Nicotinamide riboside (NR) | Nicotinamide riboside (NR) + resveratrol (R) | Placebo | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline, mean (standard deviation) | Follow-up, mean (standard deviation) | Within group change, LSMeans (standard error) | Baseline, mean (standard deviation) | Follow-up, mean (standard deviation) | Within group change, LSMeans (standard error) | Baseline, mean (standard deviation) | Follow-up, mean (standard deviation) | Within group change, LSMeans (standard error) | NR vs. placebo, LSMeans (90% CI) | NR + R vs. placebo, LSMeans (90% CI) | |
Exploratory outcomes | |||||||||||
Satellite cells (satellite cells/100 fibers) | 28.04 (20.66) N = 7 | 25.76 (11.28) N = 7 | 1.73 (4.52) | 18.90 (10.56) N = 4 | 19.53 (15.11) N = 4 | −3.36 (4.33) | 18.30 (11.21) N = 5 | 12.27 (5.66) N = 5 | −9.41 (3.80) | 11.14 (2.16, +∞) P = 0.060 | 6.05 (−1.86, +∞) P = 0.16 |
Type 1 fibers (%) | 37.94 (19.57) N = 7 | 39.80 (19.29) N = 7 | 0.17 (4.86) | 59.82 (20.04) N = 4 | 52.05 (13.45) N = 4 | −5.94 (4.88) | 56.79 (14.04) N = 5 | 50.34 (16.50) N = 5 | −5.04 (4.12) | 5.21 (−4.47, +∞) P = 0.24 | −0.90 (−9.52, +∞) P = 0.56 |
NAD+ (pmol/mg) | 85.82 (59.93) N = 7 | 96.68 (47.85) N = 7 | −13.99 (23.44) | 120.61 (81.06) N = 5 | 142.65 (72.38) N = 5 | 31.39 (22.57) | 92.33 (59.14) N = 5 | 105.71 (46.95) N = 5 | 21.14 (20.03) | −35.13 (−81.20, +∞) P = 0.84 | 10.25 (−31.79, +∞) P = 0.37 |
